CD8A and neoplasm: Targeting the cholesterol metabolism of tumors through sterol O-acyltransferase 1 (SOAT1)-targeted drugs alters tumor cholesterol metabolism and increases CD8+ T lymphocytes and neutrophils, thus preventing HCC development [129].